Caris Life Sciences, Inc. Common Stock (CAI)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $6.61B
Last updated: Nov 17, 2026 at 11:04 AM ET
Caris Life Sciences, Inc. Common Stock (CAI) Stock Forecast
Analysts expect Caris Life Sciences, Inc. Common Stock (CAI) to earn $0.11 per share in the fiscal year ending Dec 31, 2026, on revenue of $1.05B. Of 14 analysts, 10 rate the stock Buy or Strong Buy, 4 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 3 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 14 ratings average 2.21, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 71% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 7.1% |
| Buy | 9 | 64.3% |
| Hold | 4 | 28.6% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 14
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 163.6% and revenue estimates rise 19.0%.
- Fiscal year ending Dec 31, 2026
- $0.11
- EPS consensus, revenue $1.05B
- Fiscal year ending Dec 31, 2027
- $0.29
- EPS consensus, revenue $1.25B
- Next report
- Feb 24, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.11 | $0.09 to $0.17 | 10 | $1.05B | $1.04B to $1.06B | 13 |
| Dec 31, 2027 | $0.29 | $0.11 to $0.40 | 10 | $1.25B | $1.19B to $1.31B | 14 |
Quarterly Estimates
The EPS consensus falls from $0.08 for the quarter ending Dec 31, 2026 to $0.04 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.08 | $0.05 to $0.20 | 14 | $292.35M | $280.28M to $308.90M | 14 |
| Mar 31, 2027 | $0.04 | $0.02 to $0.07 | 7 | $272.84M | $259.40M to $283.30M | 11 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 3 upward and 6 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 3 |
| Fiscal year ending Dec 31, 2027 | 2 | 3 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has fallen 21.4% from $0.14.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $0.11 | $0.14 | $0.14 | $0.14 | $0.14 | -20.6% |
| Fiscal year ending Dec 31, 2027 | $0.29 | $0.37 | $0.37 | $0.38 | $0.38 | -23.0% |
| Quarter ending Mar 31, 2027 | $0.04 | $0.05 | $0.05 | $0.05 | $0.05 | -20.2% |
Frequently Asked Questions About CAI
What is the CAI stock forecast?
Consensus analyst estimates put Caris Life Sciences, Inc. Common Stock's EPS at $0.11 for the fiscal year ending Dec 31, 2026, on revenue of $1.05B. The consensus rating from 14 analysts is Buy.
How do analysts rate CAI stock?
Of 14 analysts covering Caris Life Sciences, Inc. Common Stock, 1 rates it Strong Buy, 9 Buy, 4 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from CAI next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $0.11, with estimates from $0.09 to $0.17 from 10 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $0.29, with estimates from $0.11 to $0.40 from 10 analysts.
What revenue do analysts expect from Caris Life Sciences, Inc. Common Stock next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $1.05B, with estimates from $1.04B to $1.06B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $1.25B, with estimates from $1.19B to $1.31B.
How many analysts cover CAI?
14 analysts rate Caris Life Sciences, Inc. Common Stock stock, and 10 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
CAI pages: Overview, Forecast, Financials, Valuation, Competitors